|
| |
GalapagosWe are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected diseases areas for which there is a need for effective and safe medicines.
We focus on developing drugs that stop or reverse a disease state using novel targets that we identify through a patent protected genomics platform. To maximise the potential of the proprietary technology, we provide access to our target and drug discovery platform through our services division BioFocus DPI.Galapagos focuses its internal programs on developing new drugs in the bone and joint diseases- osteoarthritis, osteoporosis and rheumatoid arthritis. BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery to validation and drug discovery services through to delivery of pre-clinical candidates. In addition, BioFocus DPI provides adenoviral reagents for rapid identification and validation of novel drug targets, natural and synthetic compound libraries for screening, and compound management facilities for compound delivery to multiple screening centers.
| Contact Details: |
| BioFocus DPI9640 Towne Centre Drive |
| San Diego |
| California |
| 92121 |
| United States of America |
| Tel: | 1 858 455 8600 |
| Fax: | 1 858 546 3081 |
| Email: | bd@glpg.com |
| WWW: | www.galadeno.com/
|
|
Loading...
|
Recent Publications by Galapagos: |  |
Wnt signaling and potential applications in bone diseases.
In the United States, it is estimated that $10-15 billion is spent... | 5th August, 2008
| Galapagos, 102 Gustave Roussel, 93230 Romainville, France.
| Curr Drug Targets. 2008 Jul;9(7):581-90.
|
Preventing establishment: an inventory of introduced plants in Puerto Villamil, Isabela Island, Galapagos.
As part of an island-wide project to identify and eradicate potentially... | 17th July, 2008
| Charles Darwin Research Station, Puerto Ayora, Galapagos, Ecuador.
| PLoS ONE. 2007 Oct 17;2(10):e1042.
DOI Direct Link |
A convenient clinically relevant model of human breast cancer bone metastasis.
Breast cancer patients with advanced disease exhibit bone metastases,... | 5th June, 2008
| Galapagos SASU, 102 route de Noisy, Romainville, 93230, France.
| Clin Exp Metastasis. 2008;25(1):33-42. Epub 2007 Sep 28.
DOI Direct Link |
Expression, purification and characterization of murine Dkk1 protein.
Dickkopf-1 (Dkk1) protein is a secreted inhibitor of canonical Wnt... | 6th May, 2008
| Galapagos SASU, Protein Sciences, 102 route de Noisy, 93230 Romainville,
| Protein Expr Purif. 2008 Jul;60(1):74-81. Epub 2008 Mar 31.
DOI Direct Link |
Bone disease drug discovery: examining the interactions between osteoblast and osteoclast.
BACKGROUND: Existing drugs, including bisphosphonates and calcitonin,... | 14th March, 2008
| BioFocus DPI, A Galapagos Company, Division of Medicinal Chemistry, 9640
| Expert Opin Ther Targets. 2008 Feb;12(2):239-51.
DOI Direct Link |
→View more Galapagos research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 188 times since April 2007, the link to the organisation's website has been followed 45 times Recent Search Terms used to find this page: e-mail Galapagos Romainville | galapagos dkk1 | Galapagos Dkk-1 | HDAC6 biofocus dpi | drugs plants on galapagos | . Search for more companies in San Diego Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Galapagos |
